Guided Therapeutics (GTHP) Net Cash Flow (2011 - 2025)
Guided Therapeutics (GTHP) reported Net Cash Flow of -$24000.0 for Q4 2025, down 112.37% on a YoY basis from $194000.0 in Q4 2024, and up 75.0% sequentially from -$96000.0 in Q3 2025.
Guided Therapeutics (GTHP) Net Cash Flow (2011 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 15 years of Net Cash Flow data on file, last reported at -$24000.0 in Q4 2025.
- For the quarter ending Q4 2025, Net Cash Flow fell 112.37% year-over-year to -$24000.0; the trailing twelve-month figure through Dec 2025 stood at -$323000.0 (down 59.11% YoY), and the FY2025 full-year result was -$325000.0, down 60.1% from the prior year.
- Net Cash Flow climbed to -$24000.0 in Q4 2025, from -$96000.0 in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $2.2 million in Q3 2022 to a low of -$627000.0 in Q3 2023.
- A 5-year average of -$5150.0 and a median of -$143000.0 in 2023 frame the typical range for Net Cash Flow.
- Across the five-year window, Net Cash Flow jumped 690.03% in 2022 and slumped 680.49% in 2023, its largest moves.
- Tracing GTHP's Net Cash Flow over 5 years: stood at $102000.0 in 2021, then tumbled by 476.47% to -$384000.0 in 2022, then jumped by 63.54% to -$140000.0 in 2023, then jumped by 238.57% to $194000.0 in 2024, then plunged by 112.37% to -$24000.0 in 2025.
- Business Quant data shows GTHP's Net Cash Flow at -$24000.0 in Q4 2025, -$96000.0 in Q3 2025, and $70000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -1.70 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.11 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 768.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -503.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -500.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 202.10 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -282.15 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -2.19 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | -24,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -24,000.00 |
| Dec 31, 2025 | -24,000.00 |
| Sep 30, 2025 | -96,000.00 |
| Sep 30, 2025 | -96,000.00 |
| Jun 30, 2025 | 70,000.00 |
| Jun 30, 2025 | 70,000.00 |
| Mar 31, 2025 | -273,000.00 |
| Mar 31, 2025 | -273,000.00 |
| Dec 31, 2024 | 194,000.00 |
| Dec 31, 2024 | 194,000.00 |
| Sep 30, 2024 | -81,000.00 |
| Sep 30, 2024 | -81,000.00 |
| Jun 30, 2024 | -170,000.00 |
| Jun 30, 2024 | -170,000.00 |
| Mar 31, 2024 | -146,000.00 |
| Mar 31, 2024 | -146,000.00 |
| Dec 31, 2023 | -140,000.00 |
| Dec 31, 2023 | -140,000.00 |
| Sep 30, 2023 | -627,000.00 |
| Sep 30, 2023 | -627,000.00 |